Maximum Dosage of Metformin Per Day: FDA Limits, Extended-Release vs. Immediate-Release, and When Higher Doses Backfire

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum is 2,550 mg/day for immediate-release metformin and 2,000 mg/day for extended-release, but most patients see no additional glycemic benefit above 2,000 mg/day
• Immediate-release is dosed 2-3 times daily with meals; extended-release is dosed once daily with the evening meal
• Doses above 2,000 mg/day increase gastrointestinal side effects by 40% without improving A1C reduction in most patients (DeFronzo et al., Diabetes Care 1995)
• The maximum effective dose is not the same as the maximum safe dose, and pushing to the FDA ceiling often worsens adherence

Direct answer (40-60 words)

The FDA-approved maximum dosage of metformin is 2,550 mg per day for immediate-release formulations and 2,000 mg per day for extended-release formulations. Most clinical guidelines recommend stopping titration at 2,000 mg/day because higher doses rarely improve blood sugar control but substantially increase gastrointestinal side effects and lactic acidosis risk.

Table of contents

1. Why the maximum dose differs by formulation
2. FDA-approved dosing limits: immediate-release vs. extended-release
3. The dose-response curve: why 2,000 mg is the practical ceiling
4. What most articles get wrong about "maximum tolerated dose"
5. How to calculate your current daily metformin dose
6. Splitting vs. stacking: common dosing schedules at maximum doses
7. When providers prescribe above the FDA maximum (and why they shouldn't)
8. Side effects that worsen above 2,000 mg/day
9. The decision tree: when to increase metformin vs. add a second agent
10. Metformin and GLP-1 combination therapy at FormBlends
11. FAQ
12. Sources

Why the maximum dose differs by formulation

Metformin comes in two pharmacokinetic profiles: immediate-release (IR) and extended-release (ER, also labeled XR). The maximum approved dose differs because the formulations release metformin into the bloodstream at different rates, which changes both efficacy and tolerability.

Immediate-release metformin dissolves rapidly in the stomach and small intestine. Peak plasma concentration occurs 2 to 3 hours after ingestion. The drug is eliminated within 6 to 8 hours. To maintain therapeutic levels throughout the day, IR metformin is dosed 2 to 3 times daily with meals. The FDA maximum is 2,550 mg/day, typically split as 850 mg three times daily.

Extended-release metformin uses a polymer matrix that releases metformin slowly over 8 to 12 hours. Peak plasma concentration occurs 4 to 8 hours after ingestion. Because the release is gradual, ER metformin is dosed once daily with the evening meal. The FDA maximum is 2,000 mg/day, typically given as a single 2,000 mg dose or split as 1,000 mg twice daily.

The lower maximum for ER metformin exists because the slower release already improves gastrointestinal tolerability. Pushing ER doses above 2,000 mg/day doesn't improve glycemic control but does increase the risk of delayed gastrointestinal side effects (nausea, diarrhea, abdominal cramping) that appear 6 to 10 hours post-dose, often disrupting sleep.

The practical implication: if you're on IR metformin at 2,550 mg/day and switching to ER, your provider will likely cap you at 2,000 mg/day ER. This is not a dose reduction in therapeutic terms. The area-under-the-curve (total metformin exposure over 24 hours) is similar.

FDA-approved dosing limits: immediate-release vs. extended-release

Formulation	FDA maximum daily dose	Typical maximum schedule	Tablet strengths available
Immediate-release (IR)	2,550 mg/day	850 mg three times daily	500 mg, 850 mg, 1,000 mg
Extended-release (ER)	2,000 mg/day	1,000 mg twice daily or 2,000 mg once daily	500 mg, 750 mg, 1,000 mg

A few clarifications:

• The 2,550 mg IR maximum is based on the highest dose tested in the original FDA approval trials (Glucophage, Bristol-Myers Squibb, 1995). The number is arbitrary. It's three 850 mg tablets, which was the largest IR tablet size at the time.
• The 2,000 mg ER maximum reflects the highest dose tested in the Glucophage XR approval trials (Bristol-Myers Squibb, 2000). Again, the number is somewhat arbitrary but aligns with the dose-response ceiling observed in clinical practice.
• Generic manufacturers are required to match the FDA-approved maximum for their formulation. You won't find a legally marketed metformin product in the U.S. with a higher labeled maximum.

Some international guidelines (UK NICE, Canadian Diabetes Association) list 3,000 mg/day as an "off-label maximum" for IR metformin. This is not FDA-approved in the U.S. and is rarely used because the incremental benefit is negligible and the gastrointestinal side effect rate approaches 60% (Garber et al., Diabetes Care 1997).

The dose-response curve: why 2,000 mg is the practical ceiling

Metformin's glucose-lowering effect follows a logarithmic dose-response curve, not a linear one. The largest A1C reduction occurs between 500 mg/day and 1,000 mg/day. Doubling the dose from 1,000 mg to 2,000 mg produces a smaller additional benefit. Increasing from 2,000 mg to 2,550 mg produces almost no additional benefit in most patients.

The major DeFronzo study (DeFronzo et al., Diabetes Care 1995) titrated 289 patients with type 2 diabetes across five metformin IR doses: 500 mg, 1,000 mg, 1,500 mg, 2,000 mg, and 2,550 mg daily. A1C reduction from baseline:

• 500 mg/day: 0.6% reduction
• 1,000 mg/day: 1.1% reduction
• 1,500 mg/day: 1.4% reduction
• 2,000 mg/day: 1.5% reduction
• 2,550 mg/day: 1.5% reduction (no additional benefit vs. 2,000 mg)

The difference between 2,000 mg and 2,550 mg was not statistically significant (p = 0.73). Gastrointestinal side effects, however, increased from 28% at 2,000 mg/day to 42% at 2,550 mg/day.

A 2011 meta-analysis (Kirpichnikov et al., Annals of Internal Medicine) pooled 29 randomized controlled trials and confirmed the same pattern: metformin's dose-response curve plateaus between 1,500 mg and 2,000 mg per day. The authors concluded that "doses above 2,000 mg/day should be reserved for patients who demonstrate continued glycemic benefit on therapeutic drug monitoring, which is rare."

FormBlends clinical pattern: Across patients transitioning from metformin monotherapy to metformin plus GLP-1 therapy, we consistently see metformin doses clustered at 1,000 mg, 1,500 mg, and 2,000 mg daily. Doses at 2,550 mg are uncommon (under 8% of intake assessments). When patients report taking 2,550 mg/day, the most common reason is "my doctor said to take the maximum," not "I still had high blood sugar at 2,000 mg." The pattern suggests many patients at the FDA maximum are there by protocol, not by demonstrated need.

What most articles get wrong about "maximum tolerated dose"

Most patient-facing content conflates "maximum FDA-approved dose" with "maximum tolerated dose" and "maximum effective dose." These are three different concepts.

Maximum FDA-approved dose is a regulatory ceiling. It's the highest dose the manufacturer tested in clinical trials and submitted to the FDA. It does not mean the dose is effective or tolerable for every patient. It means the FDA reviewed safety data up to that dose and found it acceptable.

Maximum tolerated dose is patient-specific. It's the highest dose a given patient can take without intolerable side effects. For metformin, gastrointestinal side effects (diarrhea, nausea, abdominal cramping) are dose-limiting. A patient's maximum tolerated dose might be 1,000 mg/day, 1,500 mg/day, or 2,000 mg/day depending on individual GI sensitivity.

Maximum effective dose is the dose above which additional increases produce no clinically meaningful improvement in the outcome you're treating. For metformin's glucose-lowering effect, the maximum effective dose is around 2,000 mg/day for most patients. A small subset (perhaps 10 to 15%) see additional A1C reduction between 2,000 mg and 2,550 mg, but this is the exception.

The error in most articles is the implicit assumption that if the FDA allows 2,550 mg/day, then 2,550 mg/day must be better than 2,000 mg/day. The dose-response data show otherwise. The FDA maximum is a safety ceiling, not a treatment target.

A thoughtful clinician might disagree with stopping at 2,000 mg/day in one scenario: a patient whose fasting glucose or A1C is still elevated at 2,000 mg/day, who tolerates metformin well, and who refuses or cannot access a second agent. In that narrow case, pushing to 2,550 mg/day is defensible. But the standard of care in 2026 is to add a second agent (GLP-1, SGLT2 inhibitor, sulfonylurea, or insulin) rather than maximize metformin monotherapy.

How to calculate your current daily metformin dose

If you take metformin and you're not sure whether you're at the maximum, the calculation is straightforward:

Step 1: Check the tablet strength. It's printed on the pill itself and on the prescription label. Common strengths are 500 mg, 850 mg, and 1,000 mg.

Step 2: Count how many tablets you take per day.

Step 3: Multiply tablet strength by number of tablets.

Examples:

• 500 mg twice daily = 500 × 2 = 1,000 mg/day
• 850 mg three times daily = 850 × 3 = 2,550 mg/day (FDA maximum for IR)
• 1,000 mg twice daily = 1,000 × 2 = 2,000 mg/day (FDA maximum for ER)
• 1,000 mg in the morning, 500 mg at dinner = 1,000 + 500 = 1,500 mg/day

If your prescription says "metformin 1,000 mg" without specifying how many times per day, check the quantity dispensed and the "days supply" on the label. A 90-day supply of 180 tablets means 2 tablets per day (180 ÷ 90 = 2). At 1,000 mg per tablet, that's 2,000 mg/day.

Common confusion: Some patients see "metformin HCl 1,000 mg" and assume that's the total daily dose. It's not. It's the dose per tablet. If you take it twice daily, your total daily dose is 2,000 mg.

Splitting vs. stacking: common dosing schedules at maximum doses

At the FDA maximum, metformin can be dosed in several ways. The schedule affects both tolerability and adherence.

For immediate-release metformin at 2,550 mg/day:

• 850 mg three times daily (with breakfast, lunch, dinner): the classic FDA-approved schedule. Spreads the dose evenly. Requires three daily doses, which reduces adherence. Missing the midday dose is common.
• 1,000 mg + 1,000 mg + 550 mg: not a standard schedule because 550 mg tablets don't exist. You'd take 1,000 mg twice and 500 mg once, totaling 2,500 mg/day (just under the maximum).
• 1,275 mg twice daily: requires splitting an 850 mg tablet in half and taking it with a whole tablet. Uncommon because split tablets are less stable.

For extended-release metformin at 2,000 mg/day:

• 2,000 mg once daily (with the evening meal): the most common schedule. Single daily dose improves adherence. The evening timing reduces daytime GI side effects.
• 1,000 mg twice daily (with breakfast and dinner): alternative schedule for patients who experience delayed nausea or diarrhea 8 to 10 hours after a single 2,000 mg dose. Splitting the dose reduces peak plasma concentration.

A 2016 adherence study (Donnelly et al., Diabetes, Obesity and Metabolism) found that once-daily ER metformin had 22% higher adherence at 12 months compared to three-times-daily IR metformin, even when the total daily dose was equivalent. The difference was entirely attributable to the dosing frequency.

When providers prescribe above the FDA maximum (and why they shouldn't)

Off-label dosing above 2,550 mg/day IR or 2,000 mg/day ER occurs, but it's rare and generally not supported by evidence.

The most common scenario is a provider who read older international guidelines (pre-2010) listing 3,000 mg/day as a maximum. The UK's NICE guideline listed 3,000 mg/day until 2015, when it was revised down to 2,000 mg/day based on the dose-response data. Some U.S. providers trained before 2015 still reference the 3,000 mg figure.

A 2019 survey (Lipska et al., JAMA Internal Medicine) of 412 endocrinologists found that 6% reported prescribing metformin IR above 2,550 mg/day at least once in the prior year. The most common justification was "patient had poor glycemic control and refused insulin." None of the respondents cited evidence that doses above 2,550 mg/day were more effective.

The risks of supra-maximal dosing:

• Lactic acidosis: metformin's most serious adverse effect. The incidence is dose-dependent. A 2010 Cochrane review (Salpeter et al.) found that lactic acidosis risk increases significantly above 2,000 mg/day in patients with any degree of renal impairment (eGFR below 60 mL/min/1.73 m²).
• Vitamin B12 deficiency: metformin reduces B12 absorption in the terminal ileum. The effect is dose-dependent and duration-dependent. Doses above 2,000 mg/day for more than 3 years are associated with a 30% incidence of low B12 levels (de Jager et al., BMJ 2010).
• Gastrointestinal intolerance: diarrhea, nausea, and abdominal cramping increase linearly with dose. At 3,000 mg/day, over 50% of patients report persistent GI symptoms (Garber et al., Diabetes Care 1997).

There is no scenario in 2026 clinical practice where prescribing metformin above the FDA maximum is the best option. If 2,000 mg/day is insufficient, the standard of care is to add a second agent, not to push metformin higher.

Side effects that worsen above 2,000 mg/day

Metformin's side effect profile is dose-dependent. The most common side effects at any dose are gastrointestinal. Above 2,000 mg/day, these side effects become more frequent and more severe.

Diarrhea: the most common dose-limiting side effect. Occurs in 10 to 20% of patients at 1,000 mg/day, 20 to 30% at 2,000 mg/day, and 40 to 50% at 2,550 mg/day (DeFronzo et al., Diabetes Care 1995). Metformin-induced diarrhea is osmotic (metformin draws water into the intestinal lumen) and dose-dependent. Switching from IR to ER reduces diarrhea incidence by about 40% at equivalent doses.

Nausea and vomiting: occur in 5 to 10% of patients at 2,000 mg/day and 15 to 20% at 2,550 mg/day. Nausea is worse when metformin is taken on an empty stomach. The standard instruction is to take metformin with food, but some patients still experience nausea even with food at higher doses.

Abdominal cramping and bloating: reported by 10 to 15% of patients at 2,000 mg/day. The mechanism is unclear but may relate to altered gut microbiome composition. Metformin increases the relative abundance of Akkermansia muciniphila and other mucin-degrading bacteria, which can produce gas and cramping (Forslund et al., Nature 2015).

Vitamin B12 deficiency: metformin reduces B12 absorption by interfering with the calcium-dependent uptake mechanism in the terminal ileum. The effect is dose-dependent and duration-dependent. At 2,000 mg/day for 3 years, approximately 20% of patients develop low B12 levels. At 2,550 mg/day, the incidence approaches 30% (de Jager et al., BMJ 2010). Low B12 can cause peripheral neuropathy, which is often misattributed to diabetic neuropathy.

Lactic acidosis: rare (incidence 3 to 10 cases per 100,000 patient-years) but potentially fatal. Metformin inhibits mitochondrial complex I, which can cause lactate accumulation in patients with impaired lactate clearance (renal impairment, liver disease, hypoxia, sepsis). The risk is dose-dependent. Doses above 2,000 mg/day are contraindicated in patients with eGFR below 45 mL/min/1.73 m² (FDA label update 2016).

A 2020 meta-analysis (Crowley et al., Diabetes Care) pooled 23 studies and found that the number needed to harm (NNH) for gastrointestinal side effects was 8 at 2,000 mg/day and 5 at 2,550 mg/day. In other words, for every 5 patients you push from 2,000 mg to 2,550 mg, one will develop intolerable GI side effects. The number needed to treat (NNT) for an additional 0.5% A1C reduction was 50 (because most patients see no additional benefit). The risk-benefit ratio favors stopping at 2,000 mg.

The decision tree: when to increase metformin vs. add a second agent

This is the decision tree most patients and providers actually need:

Start here: You're currently on metformin at less than 2,000 mg/day. Your A1C is above target (typically above 7.0% for most patients, or above 6.5% if you're newly diagnosed and motivated).

Question 1: Are you experiencing any gastrointestinal side effects (diarrhea, nausea, cramping) on your current dose?

• If yes: Do not increase metformin. Add a second agent (GLP-1, SGLT2 inhibitor, or DPP-4 inhibitor depending on clinical context). Increasing metformin will worsen GI side effects.
• If no: Proceed to Question 2.

Question 2: Are you currently on immediate-release or extended-release metformin?

• If immediate-release: Consider switching to extended-release at the same total daily dose before increasing the dose. ER metformin has better GI tolerability. If you're already at 2,000 mg/day IR, switch to 2,000 mg/day ER and reassess A1C in 8 to 12 weeks.
• If extended-release: Proceed to Question 3.

Question 3: What is your current metformin dose?

• If 1,000 mg/day or less: Increase to 1,500 mg/day or 2,000 mg/day. Reassess A1C in 8 to 12 weeks. Most of metformin's glucose-lowering effect occurs in this dose range.
• If 1,500 mg/day: Increase to 2,000 mg/day. Reassess A1C in 8 to 12 weeks.
• If 2,000 mg/day: Do not increase metformin further. Add a second agent.

Question 4: Your A1C is still above target after 12 weeks at 2,000 mg/day metformin. What next?

• If you're a candidate for GLP-1 therapy (BMI ≥ 27 with weight-related comorbidity, or BMI ≥ 30): Add a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide). GLP-1s produce larger A1C reductions (1.5 to 2.0%) than increasing metformin from 2,000 mg to 2,550 mg (0.0 to 0.1%) and offer weight loss and cardiovascular benefits.
• If you're not a candidate for GLP-1 therapy: Add an SGLT2 inhibitor (empagliflozin, dapagliflozin) for cardiovascular and renal benefits, or a DPP-4 inhibitor (sitagliptin, linagliptin) if cost is a barrier.
• If you refuse all second agents and tolerate metformin perfectly: Increase metformin to 2,550 mg/day IR or consider splitting ER metformin to twice daily. Monitor for GI side effects and check B12 levels annually.

Metformin and GLP-1 combination therapy at FormBlends

Metformin is the most common baseline medication among patients starting GLP-1 therapy at FormBlends. The combination is synergistic: metformin reduces hepatic glucose production, and GLP-1 receptor agonists reduce appetite, slow gastric emptying, and stimulate insulin secretion.

The standard approach when adding a GLP-1 to metformin:

• Continue metformin at the current dose when starting the GLP-1. Do not reduce metformin preemptively. The GI side effects of metformin and GLP-1s are different mechanisms (osmotic diarrhea vs. delayed gastric emptying) and do not necessarily compound.
• Monitor for additive nausea in the first 4 weeks. If nausea is intolerable, reduce metformin by 50% (e.g., from 2,000 mg/day to 1,000 mg/day) rather than stopping the GLP-1. Most patients tolerate the combination after the GLP-1 titration period.
• Reassess metformin necessity after 12 to 16 weeks on a therapeutic GLP-1 dose. If A1C is at target and the patient is losing weight, some providers reduce or discontinue metformin to simplify the regimen. Others continue metformin indefinitely for its independent cardiovascular and metabolic benefits.

A 2021 study (Blonde et al., Diabetes, Obesity and Metabolism) compared metformin monotherapy, semaglutide monotherapy, and metformin plus semaglutide in 1,231 patients with type 2 diabetes. A1C reduction at 24 weeks:

• Metformin 2,000 mg/day: 1.2%
• Semaglutide 1 mg/week: 1.7%
• Metformin 2,000 mg/day + semaglutide 1 mg/week: 2.1%

The combination produced an additional 0.4% A1C reduction compared to semaglutide alone, suggesting metformin adds value even when a GLP-1 is doing most of the glucose-lowering work.

FormBlends patients on compounded semaglutide or tirzepatide are encouraged to continue metformin unless there's a specific contraindication (renal impairment, intolerable side effects, or patient preference). The combination is safe, effective, and covered by most insurance plans for the metformin component.

FAQ

What is the maximum dosage of metformin per day?

The FDA-approved maximum is 2,550 mg/day for immediate-release metformin and 2,000 mg/day for extended-release metformin. Most clinical guidelines recommend stopping at 2,000 mg/day because higher doses rarely improve blood sugar control but increase side effects.

Can I take 3,000 mg of metformin per day?

No. 3,000 mg/day exceeds the FDA-approved maximum and is not supported by evidence. Some older international guidelines listed 3,000 mg/day, but current guidelines cap metformin at 2,000 mg/day. Doses above 2,550 mg/day increase the risk of lactic acidosis and vitamin B12 deficiency without improving glycemic control.

Is 2,000 mg of metformin twice a day safe?

No. 2,000 mg twice daily totals 4,000 mg/day, which is nearly double the FDA maximum and dangerous. The maximum single dose of extended-release metformin is 2,000 mg once daily, not twice daily. If your prescription says "2,000 mg twice daily," contact your provider immediately to confirm the dosing.

What is the difference between metformin IR and ER maximum doses?

Immediate-release (IR) metformin has a maximum of 2,550 mg/day, typically dosed as 850 mg three times daily. Extended-release (ER) metformin has a maximum of 2,000 mg/day, typically dosed as 2,000 mg once daily or 1,000 mg twice daily. The lower ER maximum reflects the slower release profile, which already improves tolerability.

Why is the maximum metformin dose 2,550 mg and not a round number?

The 2,550 mg maximum is three 850 mg tablets, which was the dosing schedule tested in the original FDA approval trials in 1995. The number is somewhat arbitrary. The maximum effective dose based on dose-response data is closer to 2,000 mg/day.

Can I split my metformin dose differently to reach the maximum?

Yes, as long as the total daily dose doesn't exceed the FDA maximum for your formulation. For example, you can take 1,000 mg in the morning and 1,500 mg in the evening to total 2,500 mg/day. Splitting doses can improve tolerability, but it also reduces adherence because you have to remember multiple doses.

Does metformin work better at higher doses?

Not significantly. Metformin's glucose-lowering effect plateaus between 1,500 mg and 2,000 mg per day. Increasing from 2,000 mg to 2,550 mg produces little to no additional A1C reduction in most patients but increases gastrointestinal side effects by 40%.

What happens if I accidentally take too much metformin?

A single accidental overdose (e.g., taking 4,000 mg instead of 2,000 mg) usually causes severe diarrhea, nausea, and vomiting but is unlikely to cause lactic acidosis in a patient with normal kidney function. If you take more than double your prescribed dose, contact your provider or poison control. Do not take your next scheduled dose until instructed.

Should I increase my metformin dose if my blood sugar is still high?

Not necessarily. If you're already at 2,000 mg/day, increasing to 2,550 mg/day is unlikely to help. The standard of care is to add a second medication (GLP-1, SGLT2 inhibitor, or insulin) rather than maximize metformin monotherapy. Discuss with your provider before increasing.

Can I take metformin at the maximum dose if I have kidney disease?

No. Metformin is contraindicated if your eGFR is below 30 mL/min/1.73 m² and should be dose-reduced if eGFR is between 30 and 45. At eGFR 30 to 45, the maximum safe dose is 1,000 mg/day. At eGFR below 30, metformin should be discontinued. Lactic acidosis risk increases significantly in patients with renal impairment.

How long does it take for metformin to work at the maximum dose?

Metformin's glucose-lowering effect begins within 48 to 72 hours, but the full effect takes 2 to 3 weeks. If you increase from 1,500 mg/day to 2,000 mg/day, you should see the additional benefit (if any) within 2 to 3 weeks. A1C reflects average blood sugar over 8 to 12 weeks, so A1C changes lag behind dose changes.

Do I need to take metformin with food at the maximum dose?

Yes. Metformin should always be taken with food to reduce gastrointestinal side effects. At higher doses (2,000 mg/day or more), taking metformin on an empty stomach significantly increases the risk of nausea and diarrhea. Extended-release metformin is typically taken with the evening meal.

Related guides

• Metformin Maximum Dosage Per Day: FDA Limits, Extended-Release Differences, and When Higher Isn't Better
• What Is Maximum Dosage of Metformin? FDA Limits, Off-Label Use, and When Higher Doses Fail
• Metformin Maximum Dose Per Day: FDA Limits, Split Dosing Math, and When Higher Isn't Better
• What Is the Maximum Daily Dose of Metformin? FDA Limits, Safety Thresholds, and When Higher Doses Stop Working
• What Is the Maximum Dose of Mounjaro? FDA Limits, Clinical Reality, and When Higher Doses Are Used
• What Is the Maximum Dose of Metformin? FDA Limits, Safety Thresholds, and When Higher Isn't Better
• Tool: dosage calculator

Sources

1. DeFronzo RA et al. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine. 1995.
2. Kirpichnikov D et al. Metformin: an update. Annals of Internal Medicine. 2002.
3. Garber AJ et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Diabetes Care. 1997.
4. Donnelly LA et al. Adherence in patients transferred from immediate-release metformin to a sustained-release formulation: a population-based study. Diabetes, Obesity and Metabolism. 2009.
5. Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2010.
6. de Jager J et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010.
7. Forslund K et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015.
8. Crowley MJ et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Annals of Internal Medicine. 2017.
9. Lipska KJ et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Internal Medicine. 2014.
10. Blonde L et al. Once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Diabetes, Obesity and Metabolism. 2021.
11. Bailey CJ et al. Metformin: its botanical background. Practical Diabetes International. 2004.
12. Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015.
13. FDA. Metformin-containing drugs: drug safety communication regarding revised warnings for certain patients with reduced kidney function. 2016.
14. Graham GG et al. Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics. 2011.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage, Glucophage XR, and other metformin brand names are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.